NCT06856161Recruiting
A Novel Blood Test as a Biomarker in Mental Health
A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 26 Feb 2025
- Start date
- 25 Mar 2025
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Fraser Health
- Diseases
- Schizophrenia, Depression
- NCT number
- NCT06856161
What you commit to
- Study type: Observational
- Planned participants: 500
- From 25 Mar 2025 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to provide informed consent. II. Currently enrolled in any other research study involving drugs or devices that may confound mental health treatment outcomes.
Other
- Currently declared on extended leave Under British Columbia's Mental Health Act.
Who the study is looking for
- Age 19+. II. Informed consent by participant
- Any of the following situations:
- Suspected, new onset or established depression.
- First episode of psychosis or suspected/established schizophrenia. IV. In the opinion of the Investigator, the participant will likely be able to complete the standardized mental health questionnaires administered in each study visit.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Columbian Hospital Coordinator of this site? Confirm its status | New Westminster | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.